AFP and seminoma: In general, 16.9 % of patients with stage II or greater pure seminoma without elevated serum AFP levels have viable cancer cells in their retroperitoneal lymph nodes [6]; of the patients with NSGCTs who have retroperitoneal lymph node metastases, 12.2 % have viable cancer cells in their retroperitoneal lymph nodes after chemotherapy [7].